Importantly, localized increases in GLP-1, such as that occur in the gut and portal vein, often have a more profound effect than systemic elevations, emphasizing the therapeutic potential of targeting regional activity rather than relying solely on systemic concentrations
Once hydration and nutritional status are restored, therapy can resume at a lower dose, with gradual titration to minimize risks
Any theoretical combination would likely require substantially reduced doses of both compoundsperhaps 1.2-2.4 mg cagrilintide with 4-8 mg retatrutide as maximum limits, though even these suggestions are purely speculative
Competition between injectable therapies Wegovy and Zepbound has brought prices down from over $1,000 a month when they were first introduced to $499 a month currently
Concurrently, GLP-1 and GIP act synergistically to potently and persistently suppress the AgRP neurons - an effect significantly more pronounced than with GLP-1 alone, leading directly to a reduction in hunger sensation and food intake
Heart rate effects during this window may not be representative of the eventual stable-state response
